An Infectious cDNA Clone of SARS-CoV-2

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016

First case of 2019 novel coronavirus in the United States

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030

SARS and MERS: recent insights into emerging coronaviruses

de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Coutard, B., Valle, C., de Lamballerie, X. N., Canard, B., Seidah, N. G., & Decroly, É. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104742 · Cited by 1,706

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435

A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum

Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J. C., Baird, M. A., Sell, B., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,260

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Menachery, V. D., Yount, B. L., Debbink, K. M., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X., Donaldson, E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

Coronavirus biology and replication: implications for SARS-CoV-2

V’kovski, P., Kratzel, A., Steiner, S., Stalder, H., & Thiel, V. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00468-6 · Cited by 3,371

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Zang, R., Castro, M. F. G., McCune, B. T., Zeng, Q., Rothlauf, P. W., Sonnek, N. M., Liu, Z., Brulois, K. F., Wang, X., Greenberg, H. B., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc3582 · Cited by 982

Evasion of Type I Interferon by SARS-CoV-2

Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J. Y.-C., Wang, H., Menachery, V. D., Rajsbaum, R., & Shi, P.-Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108234 · Cited by 957

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature · doi:10.1038/s41586-021-03237-4 · Cited by 694

COVID-19 vaccine development and a potential nanomaterial path forward

Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 660

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

Junqueira, C., Crespo, Â. C., Ranjbar, S., de Lacerda, L., Lewandrowski, M., Ingber, J., Parry, B. A., Ravid, S., Clark, S. A., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 699

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Tarke, A., Sidney, J., Kidd, C. K., Dan, J. M., Ramirez, S. I., Yu, E. D., Mateus, J., da Silva Antunes, R., Moore, E., Rubiro, P., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100204 · Cited by 540

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission

Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · Nature · doi:10.1038/s41586-021-04245-0 · Cited by 575

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Arunachalam, P. S., Scott, M. K. D., Hagan, T., Li, C., Feng, Y., Wimmers, F., Grigoryan, L., Trisal, M., Edara, V. V., Lai, L., et al. (2021) · Nature · doi:10.1038/s41586-021-03791-x · Cited by 572

Inflammasome activation in infected macrophages drives COVID-19 pathology

Sefik, E., Qu, R., Junqueira, C., Kaffe, E., Mirza, H., Zhao, J., Brewer, J. R., Han, A., Steach, H. R., Israelow, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04802-1 · Cited by 543

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

Wei, J., Alfajaro, M. M., DeWeirdt, P. C., Hanna, R. E., Lu-Culligan, W. J., Cai, W. L., Strine, M. S., Zhang, S.-M., Graziano, V. R., Schmitz, C. O., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.028 · Cited by 568

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 506

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Cohen, K. W., Linderman, S. L., Moodie, Z., Czartoski, J., Lai, L., Mantus, G., Norwood, C., Nyhoff, L. E., Edara, V. V., Floyd, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100354 · Cited by 441

Interplay between SARS-CoV-2 and the type I interferon response

Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster

Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., & Shi, P. (2022) · Nature Medicine · doi:10.1038/s41591-022-02162-x · Cited by 409

Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant

Liu, Y., Liu, J., Johnson, B. A., Xia, H., Ku, Z., Schindewolf, C., Widen, S. G., An, Z., Weaver, S. C., Menachery, V. D., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110829 · Cited by 409

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Lederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Koenig, P.-A., Das, H., Liu, H., Kümmerer, B. M., Gohr, F. N., Jenster, L., Schiffelers, L. D. J., Tesfamariam, Y. M., Uchima, M., Wuerth, J. D., et al. (2021) · Science · doi:10.1126/science.abe6230 · Cited by 380

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03693-y · Cited by 342

COVID-19 vaccines: The status and perspectives in delivery points of view

Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Arunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C. G., Fischinger, S., Li, C., Aye, P. P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · Nature · doi:10.1038/s41586-021-03530-2 · Cited by 317

Rapid assessment of SARS-CoV-2–evolved variants using virus-like particles

Syed, A. M., Taha, T. Y., Tabata, T., Chen, I. P., Ciling, A., Khalid, M. M., Sreekumar, B. K. N., Chen, P., Hayashi, J. M., Soczek, K. M., et al. (2021) · Science · doi:10.1126/science.abl6184 · Cited by 324

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Muruato, A. E., Fontes-Garfias, C. R., Ren, P., Garcia-Blanco, M. A., Menachery, V. D., Xie, X., & Shi, P.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17892-0 · Cited by 319

Comprehensive in vivo secondary structure of the SARS-CoV-2 genome reveals novel regulatory motifs and mechanisms

Huston, N. C., Wan, H., Strine, M. S., Tavares, R. D. C. A., Wilen, C. B., & Pyle, A. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.041 · Cited by 311

Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

Vanderheiden, A., Ralfs, P., Chirkova, T., Upadhyay, A. A., Zimmerman, M. G., Bedoya, S., Aoued, H. S., Tharp, G., Pellegrini, K. L., Manfredi, C., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00985-20 · Cited by 304

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285

Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes

Ravindra, N. G., Alfajaro, M. M., Gasque, V., Huston, N. C., Wan, H., Szigeti-Buck, K., Yasumoto, Y., Greaney, A. M., Habet, V., Chow, R. D., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001143 · Cited by 258

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species

Moustaqil, M. D., Ollivier, E., Chiu, H.-P., van Tol, S., Rudolffi-Soto, P., Stevens, C. S., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D. A., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 289

In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age

Lieberman, N. A. P., Peddu, V., Xie, H. J., Shrestha, L., Huang, M.-L. W., Mears, M. C., Cajimat, M. N. B., Bente, D. A., Shi, P., Bovier, F. T., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000849 · Cited by 267

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

Zang, R., Case, J. B., Yutuc, E., Ma, X., Shen, S., Gomez Castro, M. F., Liu, Z., Zeng, Q., Zhao, H., Son, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012197117 · Cited by 240

Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2

Wu, H., Xing, N., Meng, K., Fu, B., Xue, W., Dong, P., Tang, W., Xiao, Y., Liu, G., Luo, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.005 · Cited by 224

Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia

Bernard, L., Venzon, M., Klein, J., Axelrad, J. E., Zhang, C., Sullivan, A. P., Hussey, G. A., Casanovas‐Massana, A., Noval, M. G., Valero-Jimenez, A. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33395-6 · Cited by 233

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Yuan, S., Yin, X., Meng, X., Chan, J. F., Ye, Z., Riva, L., Pache, L., Chan, C. C.-Y., Lai, P.-M., Chan, C. C., et al. (2021) · Nature · doi:10.1038/s41586-021-03431-4 · Cited by 220

A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research

Rihn, S. J., Merits, A., Bakshi, S., Turnbull, M. L., Wickenhagen, A., Alexander, A. J. T., Baillie, C., Brennan, B., Brown, F., Brunker, K., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001091 · Cited by 212

Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface

Lu-Culligan, A., Chavan, A. R., Vijayakumar, P., Irshaid, L., Courchaine, E. M., Milano, K. M., Tang, Z., Pope, S. D., Song, E., Vogels, C. B. F., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.016 · Cited by 212

Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy

Ullah, I., Prévost, J., Ladinsky, M. S., Stone, H., Lu, M., Anand, S. P., Beaudoin-Bussières, G., Symmes, K., Benlarbi, M., Ding, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.015 · Cited by 212

Accelerating antiviral drug discovery: lessons from COVID-19

von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00692-8 · Cited by 230

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Edara, V. V., Manning, K. E., Ellis, M. L., Lai, L., Moore, K. M., Foster, S. L., Floyd, K. A., Davis-Gardner, M. E., Mantus, G. E., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 209

A novel cell culture system modeling the SARS-CoV-2 life cycle

Ju, X., Zhu, Y., Wang, Y., Li, J., Zhang, J., Gong, M., Ren, W., Li, S., Zhong, J., Zhang, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009439 · Cited by 199

SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis

Bailey, A. L., Dmytrenko, O., Greenberg, L., Bredemeyer, A. L., Ma, P., Liu, J., Penna, V., Winkler, E. S., Sviben, S., Brooks, E., et al. (2021) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2021.01.002 · Cited by 193

Pharmacological activation of STING blocks SARS-CoV-2 infection

Li, M., Ferretti, M., Ying, B., Descamps, H. C., Lee, E. M., Dittmar, M., Lee, J. S., Whig, K., Kamalia, B., Dohnalová, L., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi9007 · Cited by 188

Furin Cleavage Site Is Key to SARS-CoV-2 PathogenesisPreprint

Johnson, B. A., Xie, X., Kalveram, B., Lokugamage, K. G., Muruato, A. E., Zou, J., Zhang, X., Juelich, T. L., Smith, J. K., Zhang, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.268854 · Cited by 186

Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein

Hsu, J. C.-C., Laurent-Rolle, M., Pawlak, J. B., Wilen, C. B., & Cresswell, P. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101161118 · Cited by 185

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape

Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V. D., Li, Y., Yuan, Z., Zhang, X., Muruato, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20789-7 · Cited by 160

Engineering SARS-CoV-2 using a reverse genetic system

Xie, X., Lokugamage, K. G., Zhang, X., Vu, M. N., Muruato, A. E., Menachery, V. D., & Shi, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 171

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction

Torii, S., Ono, C., Suzuki, R., Morioka, Y., Anzai, I., Fauzyah, Y., Maeda, Y., Kamitani, W., Fukuhara, T., & Matsuura, Y. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109014 · Cited by 172

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

Kuzmina, A., Khalaila, Y., Voloshin, O., Keren‐Naus, A., Cohen, L. B., Raviv, Y., Shemer‐Avni, Y., Rosenberg, E., & Taube, R. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.008 · Cited by 177

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

Ku, Z., Xie, X., Hinton, P. R., Liu, X., Ye, X., Muruato, A. E., Ng, D., Biswas, S., Zou, J., Liu, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03673-2 · Cited by 170

An overview of current COVID-19 vaccine platforms

Nagy, A., & Alhatlani, B. Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.061 · Cited by 185

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Edara, V. V., Stuart, A. B., Feng, J., Suthar, M. S., McGuire, A. T., Stamatatos, L., & Pancera, M. (2020) · Nature Communications · doi:10.1038/s41467-020-19231-9 · Cited by 162

Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis

Johnson, B. A., Zhou, Y., Lokugamage, K. G., Vu, M. N., Bopp, N. E., Crocquet-Valdes, P. A., Kalveram, B., Schindewolf, C., Liu, Y., Scharton, D., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010627 · Cited by 161

A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses

Amarilla, A. A., Sng, J. D. J., Parry, R. H., Deerain, J. M., Potter, J. R., Setoh, Y. X., Rawle, D. J., Le, T. T., Modhiran, N., Wang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23779-5 · Cited by 159

SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2

Qiao, L., Liu, J., Zhao, S., Castro, M. F. G., Laurent-Rolle, M., Dong, J., Ran, X., Damani‐Yokota, P., Tang, H., Karakousi, T. R., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.05.006 · Cited by 156

The N501Y spike substitution enhances SARS-CoV-2 transmission

Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021) · doi:10.1101/2021.03.08.434499 · Cited by 574

SARS-CoV-2 Seropositivity and Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort StudyPreprint

Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 150

Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection

Chen, J., Alfajaro, M. M., Chow, R. D.-W., Wei, J., Filler, R. B., Eisenbarth, S. C., & Wilen, C. B. (2021) · Journal of Virology · doi:10.1128/jvi.00014-21 · Cited by 153

Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells

Planès, R., Pinilla, M., Santoni, K., Hessel, A., Passemar, C., Lay, K., Paillette, P., Valadão, A. L. C., Robinson, K. S., Bastard, P., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.04.033 · Cited by 160

Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)

Rostad, C. A., Chahroudi, A., Mantus, G. E., Lapp, S. A., Teherani, M., Macoy, L., Rostad, B. S., Milla, S. S., Tarquinio, K. M., Basu, R. K., et al. (2020) · PEDIATRICS · doi:10.1542/peds.2020-018242 · Cited by 151

SARS-CoV-2 disrupts host epigenetic regulation via histone mimicry

Kee, J., Thudium, S., Renner, D. M., Glastad, K. M., Palozola, K. C., Zhang, Z., Li, Y., Lan, Y., Cesare, J., Poleshko, A. S., et al. (2022) · Nature · doi:10.1038/s41586-022-05282-z · Cited by 145

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies

Vanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134

Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal HCoVs

Rebendenne, A., Roy, P., Bonaventure, B., Valadão, A. L. C., Desmarets, L. M. B., Arnaud‐Arnould, M., Rouillé, Y., Tauziet, M., Giovannini, D., Touhami, J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01110-2 · Cited by 147

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome

Ye, C., Chiem, K., Park, J., Oladunni, F. S., Platt, R. N., Anderson, T., Almazán, F., de la Torre, J. C., & Martínez‐Sobrido, L. (2020) · mBio · doi:10.1128/mbio.02168-20 · Cited by 144

Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell

Puray‐Chavez, M., LaPak, K. M., Schrank, T. P., Elliott, J. L., Bhatt, D. P., Agajanian, M. J., Jasuja, R., Lawson, D. Q., Davis, K., Rothlauf, P. W., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109364 · Cited by 139

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replicationPreprint

Burgess, H. M., Depledge, D. P., Thompson, L., Srinivas, K. P., Grande, R. C., Vink, E. I., Abebe, J. S., Blackaby, W., Hendrick, A. G., Albertella, M. R., et al. (2021) · Genes & Development · doi:10.1101/gad.348320.121 · Cited by 143

SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients

Pontelli, M. C., Castro, Í. A., Júnior, R. B. M., Serra, L. L., Veras, F. P., Nascimento, D. C., Silva, C. M. S., Cardoso, R. D. S., Rosales, R., Gomes, R., et al. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac021 · Cited by 141

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126

Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication

Chu, J., Xing, C., Du, Y., Duan, T., Liu, S., Zhang, P., Cheng, C., Henley, J. E., Liu, X., Chen, Q., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00479-4 · Cited by 138

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

Neerukonda, S. N., Vassell, R. A., Herrup, R., Liu, S., Wang, T. T., Takeda, K., Yang, Y., Lin, T.-L., Wang, W., & Weiss, C. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248348 · Cited by 133

SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels

Eberhardt, N., Noval, M. G., Kaur, R., Amadori, L., Gildea, M. A., Sajja, S., Das, D., Cılhoroz, B., Stewart, O., Fernandez, D. M., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00336-5 · Cited by 132

An intranasal vaccine durably protects against SARS-CoV-2 variants in mice

Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 131

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Zou, J., Xia, H., Xie, X., Kurhade, C., Machado, R. R. G., Weaver, S. C., Ren, P., & Shi, P. (2022) · Nature Communications · doi:10.1038/s41467-022-28544-w · Cited by 114

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

Beaudoin-Bussières, G., Chen, Y., Ullah, I., Prévost, J., Tolbert, W. D., Symmes, K., Ding, S., Benlarbi, M., Gong, S. Y., Tauzin, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110368 · Cited by 121

Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium

Fiege, J. K., Thiede, J. M., Nanda, H. A., Matchett, W. E., Moore, P. J., Montanari, N. R., Thielen, B. K., Daniel, J. J., Stanley, E., Hunter, R. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009292 · Cited by 108

Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells

Amraei, R., Xia, C., Olejnik, J., White, M. R., Napoleon, M. A., Lotfollahzadeh, S., Hauser, B. M., Schmidt, A. G., Chitalia, V. C., Mühlberger, E., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113874119 · Cited by 113

SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function

Marchianò, S., Hsiang, T.-Y., Khanna, A., Higashi, T., Whitmore, L. S., Bargehr, J., Davaapil, H., Chang, J., Smith, E. A., Ong, L. P., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.008 · Cited by 112

SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression

Arshad, N., Laurent-Rolle, M., Ahmed, W. S., Hsu, J. C.-C., Mitchell, S. M., Pawlak, J., Sengupta, D., Biswas, K. H., & Cresswell, P. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208525120 · Cited by 119

Disparate temperature-dependent virus–host dynamics for SARS-CoV-2 and SARS-CoV in the human respiratory epithelium

V’kovski, P., Gultom, M. L., Kelly, J. N., Steiner, S., Russeil, J., Mangeat, B., Cora, E., Pezoldt, J., Holwerda, M., Kratzel, A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001158 · Cited by 132

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects

Jennewein, M. F., MacCamy, A. J., Akins, N. R., Feng, J., Homad, L. J., Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Stuart, A. B., Edara, V. V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109353 · Cited by 107

SARS-CoV-2 Quantum Sensor Based on Nitrogen-Vacancy Centers in Diamond

Li, C., Soleyman, R., Kohandel, M., & Cappellaro, P. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02868 · Cited by 111

A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation

Kang, L., He, G., Sharp, A. K., Wang, X., Brown, A. M., Michalak, P., & Weger‐Lucarelli, J. (2021) · Cell · doi:10.1016/j.cell.2021.07.007 · Cited by 97

Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing

He, X. C., Quan, S., Xu, M., Rodriguez, S., Goh, S. L., Wei, J., Fridman, A., Koeplinger, K. A., Carroll, S. S., Grobler, J. A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025866118 · Cited by 103

SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains

Radvák, P., Kwon, H., Košíková, M., Ortega‐Rodriguez, U., Xiang, R., Phue, J., Shen, R., Rozzelle, J., Kapoor, N., Rabara, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26803-w · Cited by 95

Durability of immune responses to mRNA booster vaccination against COVID-19

Arunachalam, P. S., Lai, L., Samaha, H., Feng, Y., Hu, M., Hui, H. S.-Y., Wali, B., Ellis, M. L., Davis-Gardner, M. E., Huerta, C., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167955 · Cited by 105

Transdermal Delivery Systems for Biomolecules

Peña‐Juárez, M. C., Guadarrama-Escobar, O. R., & Escobar‐Chávez, J. J. (2021) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-020-09525-2 · Cited by 99

Engineering SARS-CoV-2 using a reverse genetic system

Xie, X., Lokugamage, K. G., Zhang, X., Vu, M. N., Muruato, A. E., Menachery, V. D., & Shi, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 171

Efficient and modular reverse genetics system for rapid generation of recombinant severe acute respiratory syndrome coronavirus 2

Bae, S., & Myoung, J. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504015 · Cited by 3

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reactionPreprint

Torii, S., Ono, C., Suzuki, R., Morioka, Y., Anzai, I., Fauzyah, Y., Maeda, Y., Kamitani, W., Fukuhara, T., & Matsuura, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.23.309849 · Cited by 16

A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses

Amarilla, A. A., Sng, J. D. J., Parry, R. H., Deerain, J. M., Potter, J. R., Setoh, Y. X., Rawle, D. J., Le, T. T., Modhiran, N., Wang, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23779-5 · Cited by 159

Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2

Chiem, K., Nogales, A., Almazán, F., Ye, C., & Martínez‐Sobrido, L. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3533-9_9 · Cited by 1